What is HC Wainwright’s Forecast for VKTX Q4 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at HC Wainwright issued their Q4 2026 EPS estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, February 12th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same quarter in the previous year, the firm earned ($0.32) EPS.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Wednesday, January 21st. Zacks Research cut Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. B. Riley Financial raised shares of Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. dropped their price objective on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a report on Friday, October 24th. Finally, Canaccord Genuity Group boosted their target price on shares of Viking Therapeutics from $106.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.80.

Viking Therapeutics Trading Up 6.8%

NASDAQ:VKTX opened at $30.49 on Friday. The company has a market cap of $3.45 billion, a PE ratio of -9.59 and a beta of 0.75. The company has a 50 day simple moving average of $33.33 and a two-hundred day simple moving average of $32.61. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $43.15.

Institutional Investors Weigh In On Viking Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VKTX. Norges Bank bought a new position in shares of Viking Therapeutics during the second quarter worth $46,846,000. BNP Paribas Financial Markets increased its holdings in shares of Viking Therapeutics by 536.3% in the fourth quarter. BNP Paribas Financial Markets now owns 992,695 shares of the biotechnology company’s stock worth $34,923,000 after purchasing an additional 836,686 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Viking Therapeutics by 58.7% in the third quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company’s stock worth $54,807,000 after buying an additional 771,704 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Viking Therapeutics by 41.8% during the third quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company’s stock valued at $55,000,000 after buying an additional 616,526 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in Viking Therapeutics by 6,315.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 596,650 shares of the biotechnology company’s stock valued at $15,811,000 after buying an additional 587,350 shares in the last quarter. Institutional investors own 76.03% of the company’s stock.

Insider Activity

In other Viking Therapeutics news, COO Marianna Mancini sold 57,661 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $32.98, for a total value of $1,901,659.78. Following the completion of the transaction, the chief operating officer directly owned 409,190 shares in the company, valued at $13,495,086.20. This represents a 12.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Brian Lian sold 233,409 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $32.96, for a total transaction of $7,693,160.64. Following the sale, the chief executive officer owned 2,499,291 shares in the company, valued at $82,376,631.36. The trade was a 8.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 364,731 shares of company stock worth $12,053,627 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Key Headlines Impacting Viking Therapeutics

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Company will advance oral VK2735 into a late‑stage (Phase 3) obesity program, targeting a 3Q26 start — a key development milestone that materially derisks the asset and increases potential commercial value. Viking Therapeutics plans to advance oral obesity drug to late-stage trial
• Positive Sentiment: Subcutaneous VK2735 VANQUISH program is progressing (VANQUISH‑1 enrollment complete; VANQUISH‑2 nearing full enrollment) and a VK2735 maintenance dosing study is fully enrolled with data expected in 3Q26 — multiple near‑term readouts that could drive valuation upside. Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Company ended the quarter with a strong cash balance (~$706M) and plans an IND filing this quarter for a novel amylin agonist — provides runway to fund multiple programs and supports follow‑on development. Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Company outlined dual Phase 3 obesity programs and maintenance regimens in investor materials — strategy clarifies the development path but execution and readouts still lie ahead. Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
• Neutral Sentiment: Earnings call transcript and management commentary are available; they reiterate program timelines and funding plans — useful for modeling but not immediate catalysts beyond the pipeline news. Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Viking reported a wider‑than‑expected Q4 loss (EPS of ($1.38) vs. consensus ($0.89)), increasing near‑term cash burn and highlighting that commercial value depends on successful clinical progression. VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.